Effect of Semaglutide and Empagliflozin on Pulmonary Structure and Proteomics in Obese Mice

References

• Ponasenko A, Sinitsky M, Minina V, et al. Immune response and lipid metabolism gene polymorphisms are associated with the risk of obesity in middle-aged and elderly patients. J Pers Med. 2022;12(2):238. doi:10.3390/jpm12020238
   PubMed Web of Science ®Google Scholar
• Lustig RH, Collier D, Kassotis C, et al. Obesity I: overview and molecular and biochemical mechanisms. Biochem Pharmacol. 2022;199:115012. doi:10.1016/j.bcp.2022.115012
   PubMed Web of Science ®Google Scholar
• Watson RA, Pride NB, Thomas EL, et al. Reduction of total lung capacity in obese men: comparison of total intrathoracic and gas volumes. J Appl Physiol. 2010;108(6):1605–1612. doi:10.1152/japplphysiol.01267.2009
   PubMed Web of Science ®Google Scholar
• Behazin N, Jones SB, Cohen RI, Loring SH. Respiratory restriction and elevated pleural and esophageal pressures in morbid obesity. J Appl Physiol. 2010;108(1):212–218. doi:10.1152/japplphysiol.91356.2008
   PubMed Web of Science ®Google Scholar
• Jones RL, Nzekwu M-MU. Nzekwu MM.The effects of body mass index on lung volumes. Chest. 2006;130(3):827–833. doi:10.1378/chest.130.3.827
   PubMed Web of Science ®Google Scholar
• Sharp JT, Henry JP, Sweany SK, Meadows WR, Pietras RJ. The total work of breathing in normal and obese men. J Clin Invest. 1964;43(4):728–739. doi:10.1172/JCI104957
   PubMed Web of Science ®Google Scholar
• Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. JAMA. 2004;291(16):2013–2016. doi:10.1001/jama.291.16.2013
   PubMed Web of Science ®Google Scholar
• Mokhlesi B, Kryger MH, Grunstein RR. Assessment and management of patients with obesity hypoventilation syndrome. Proc Am Thorac Soc. 2008;5(2):218–225. doi:10.1513/pats.200708-122MG
   PubMedGoogle Scholar
• Beuther DA, Sutherland ER. Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med. 2007;175(7):661–666. doi:10.1164/rccm.200611-1717OC
   PubMed Web of Science ®Google Scholar
• Lambert AA, Putcha N, Drummond MB, et al. Obesity is associated with increased morbidity in moderate to severe COPD. Chest. 2017;151(1):68–77. doi:10.1016/j.chest.2016.08.1432
   PubMed Web of Science ®Google Scholar
• Guo X, Sunil C, Qian G. Obesity and the development of lung fibrosis. Front Pharmacol. 2022;12:812166. doi:10.3389/fphar.2021.812166
   PubMed Web of Science ®Google Scholar
• Chen Y, Wei D, Deng M. Comparative analysis of serum proteins between hepatitis B virus genotypes B and C infection by DIA-Based quantitative proteomics. Infect Drug Resist. 2021;14:4701–4715. doi:10.2147/IDR.S335666
   PubMed Web of Science ®Google Scholar
• Moulder R, Schvartz D, Goodlett DR, Dayon L. Proteomics of diabetes, obesity, and related disorders. Proteomics Clin Appl. 2018;12(1):845. doi:10.1002/prca.201600134
   Web of Science ®Google Scholar
• López-Villar E, Martos-Moreno GÁ, Chowen JA, Okada S, Kopchick JJ, Argente J. A proteomic approach to obesity and type 2 diabetes. J Cell Mol Med. 2015;19(7):1455–1470. doi:10.1111/jcmm.12600
   PubMed Web of Science ®Google Scholar
• Hanash S. Disease proteomics. Nature. 2003;422(6928):226–232. doi:10.1038/nature01514
   PubMed Web of Science ®Google Scholar
• Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B. Glucagon-like peptide 1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion. 1995;56(2):117–126. doi:10.1159/000201231
   PubMed Web of Science ®Google Scholar
• Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 1996;137(7):2968–2978. doi:10.1210/endo.137.7.8770921
   PubMed Web of Science ®Google Scholar
• Rayner CK, Jones KL, Horowitz M. Semaglutide vs placebo as an adjunct to intensive behavioral therapy and body weight in adults with overweight or obesity. JAMA. 2021;326(12):1213–1214. doi:10.1001/jama.2021.13021
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Bassock S, Engels E, et al. Semaglutide single-dose pen-injector: post hoc analysis of summative usability testing for weight management. Diabetes Obes Metab. 2021;23(11):2590–2594. doi:10.1111/dom.14509
   PubMed Web of Science ®Google Scholar
• Fandiño J, Toba L, González-Matías LC, Diz-Chaves Y, Federico M. GLP-1 receptor agonist ameliorates experimental lung fibrosis. Sci Rep. 2020;10(1):18091. doi:10.1038/s41598-020-74912-1
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334. doi:10.1056/NEJMoa1515920
   PubMed Web of Science ®Google Scholar
• Chowdhury B, Luu AZ, Luu VZ, et al. The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. Biochem Biophys Res Commun. 2020;524(1):50–56. doi:10.1016/j.bbrc.2020.01.015
   PubMed Web of Science ®Google Scholar
• Park HJ, Han H, Oh EY, et al. Empagliflozin and dulaglutide are effective against obesity-induced airway hyperresponsiveness and fibrosis in a murine model. Sci Rep. 2019;9(1):15601. doi:10.1038/s41598-019-51648-1
   PubMedGoogle Scholar
• Chen X, Chen S, Li Z, et al. Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice. Front Pharmacol. 2023;17(14):975830. doi:10.3389/fphar.2023.975830
   Google Scholar
• Chen X, Ma L, Gan K, Pan X, Chen S. Phosphorylated proteomics-based analysis of the effects of semaglutide on hippocampi of high-fat diet-induced-obese mice. Diabetol Metab Syndr. 2023;15(1):63. doi:10.1186/s13098-023-01023-y
   PubMed Web of Science ®Google Scholar
• Yue L, Chen S, Ren Q, et al. Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice. Front Endocrinol. 2022;7(13):995007. doi:10.3389/fendo.2022.995007
   Google Scholar
• Chen X, Ma L, Zhao J, Pan X, Chen S. Effect of empagliflozin on cytoskeletal repair in the hippocampus of obese mice. Front Neurosci. 2022;16:1000839. doi:10.3389/fnins.2022.1000839
   PubMed Web of Science ®Google Scholar
• Niu S, Ren Q, Chen S, et al. Metabolic and hepatic effects of empagliflozin on nonalcoholic fatty liver mice. Diabetes Metab Syndr Obes. 2023;24(16):2549–2560. doi:10.2147/DMSO.S422327
   Google Scholar
• Plubell DL, Wilmarth PA, Zhao Y, et al. Extended multiplexing of tandem mass tags (TMT) labeling reveals age and high fat diet specific proteome changes in mouse epididymal adipose tissue. Mol Cell Proteomics. 2017;16(5):873–890. doi:10.1074/mcp.M116.065524
   PubMed Web of Science ®Google Scholar
• Jaochico A, Sangaraju D, Shahidi-Latham SK. A rapid derivatization based lc-ms/ms method for quantitation of short chain fatty acids in human plasma and urine. Bioanalysis. 2019;11(8):741–753. doi:10.4155/bio-2018-0241
   PubMed Web of Science ®Google Scholar
• Pan X, Chen S, Chen X, et al. UTP14A, DKC1, DDX10, PinX1, and ESF1 modulate cardiac angiogenesis leading to obesity-induced cardiac injury. J Diabetes Res. 2022;13(2022):2923291. doi:10.1155/2022/2923291
   Google Scholar
• O’Connell JD, Paulo JA, O’Brien JJ, Gygi SP. Proteome-wide evaluation of two common protein quantification methods. J Proteome Res. 2018;17(5):1934–1942. doi:10.1021/acs.jproteome.8b00016
   PubMed Web of Science ®Google Scholar
• Gregg EW, Shaw JE. Global health effects of overweight and obesity. N Engl J Med. 2017;377(1):80–81. doi:10.1056/NEJMe1706095
   PubMed Web of Science ®Google Scholar
• Chang CW, Lee SM, Choi BW, et al. Costs attributable to overweight and obesity in working asthma patients in the United States. Yonsei Med J. 2017;58(1):187–194. doi:10.3349/ymj.2017.58.1.187
   PubMed Web of Science ®Google Scholar
• André DM, Calixto MC, Sollon C, et al. High-fat diet-induced obesity impairs insulin signaling in lungs of allergen-challenged mice: improvement by resveratrol. Sci Rep. 2017;7(1):17296. doi:10.1038/s41598-017-17558-w
   PubMedGoogle Scholar
• Singh S, Bodas M, Bhatraju NK, et al. Hyperinsulinemia adversely affects lung structure and function. Am J Physiol Lung Cell Mol Physiol. 2016;310(9):L837–45. doi:10.1152/ajplung.00091.2015
   PubMed Web of Science ®Google Scholar
• Richter G, Feddersen O, Wagner U, Barth P, Göke R, Göke B. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol. 1993;265(4 Pt 1):L374–81. doi:10.1152/ajplung.1993.265.4.L374
   PubMedGoogle Scholar
• Benito E, Blazquez E, Bosch MA. Glucagon-like peptide-1-(7-36)amide increases pulmonary surfactant secretion through a cyclic adenosine 3′,5′-monophosphate-dependent protein kinase mechanism in rat type II pneumocytes. Endocrinology. 1998;139(5):2363–2368. doi:10.1210/endo.139.5.5998
   PubMed Web of Science ®Google Scholar
• Vara E, Arias-Díaz J, Garcia C, Balibrea JL, Blázquez E. Glucagon-like peptide-1(7-36) amide stimulates surfactant secretion in human type II pneumocytes. Am J Respir Crit Care Med. 2001;163(4):840–846. doi:10.1164/ajrccm.163.4.9912132
   PubMed Web of Science ®Google Scholar
• Romaní-Pérez M, Outeiriño-Iglesias V, Moya CM, et al. Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats. Endocrinology. 2015;156(10):3559–3569. doi:10.1210/en.2014-1685
   PubMed Web of Science ®Google Scholar
• Jiang Z, Tan J, Yuan Y, Shen J, Chen Y. Semaglutide ameliorates lipopolysaccharide-induced acute lung injury through inhibiting HDAC5-mediated activation of NF-κB signaling pathway. Hum Exp Toxicol. 2022;41:9603271221125931. doi:10.1177/09603271221125931
   Web of Science ®Google Scholar
• Yang X, Feng P, Zhang X, et al. The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke. Neuropharmacology. 2019;158:107748. doi:10.1016/j.neuropharm.2019.107748
   PubMed Web of Science ®Google Scholar
• El-Horany HE, Atef MM, Ghafar MTA, et al. Empagliflozin ameliorates bleomycin-induced pulmonary fibrosis in rats by modulating Sesn2/AMPK/Nrf2 signaling and targeting ferroptosis and autophagy. Int J Mol Sci. 2023;24(11):9481. doi:10.3390/ijms24119481
   PubMed Web of Science ®Google Scholar
• Gokbulut P, Kuskonmaz SM, Koc G, et al. Evaluation of the effects of empagliflozin on acute lung injury in rat intestinal ischemia-reperfusion model. J Endocrinol Invest. 2023;46(5):1017–1026. doi:10.1007/s40618-022-01978-1
   PubMed Web of Science ®Google Scholar
• Huang D, Ju F, Du L, et al. Empagliflozin protects against pulmonary ischemia/reperfusion injury via an extracellular signal-regulated kinases 1 and 2-dependent mechanism. J Pharmacol Exp Ther. 2022;380(3):230–241. doi:10.1124/jpet.121.000956
   PubMed Web of Science ®Google Scholar
• Castoldi G, Carletti R, Ippolito S, et al. Renal anti-fibrotic effect of sodium glucose cotransporter 2 inhibition in angiotensin II-dependent hypertension. Am J Nephrol. 2020;51(2):119–129. doi:10.1159/000505144
   PubMed Web of Science ®Google Scholar
• Heo YJ, Lee N, Choi SE, et al. Empagliflozin reduces the progression of hepatic fibrosis in a mouse model and inhibits the activation of hepatic stellate cells via the hippo signalling pathway. Biomedicines. 2022;10(5):1032. doi:10.3390/biomedicines10051032
   PubMed Web of Science ®Google Scholar
• Kabel AM, Estfanous RS, Alrobaian MM. Targeting oxidative stress, proinflammatory cytokines, apoptosis and toll like receptor 4 by empagliflozin to ameliorate bleomycin-induced lung fibrosis. Respir Physiol Neurobiol. 2020;273:103316. doi:10.1016/j.resp.2019.103316
   PubMed Web of Science ®Google Scholar
• Pan X, Chen S, Chen X, et al. Effect of high-fat diet and empagliflozin on cardiac proteins in mice. Nutr Metab. 2022;19(1):69. doi:10.1186/s12986-022-00705-0
   Google Scholar
• Ge XN, Greenberg Y, Hosseinkhani MR, et al. High-fat diet promotes lung fibrosis and attenuates airway eosinophilia after exposure to cockroach allergen in mice. Exp Lung Res. 2013;39(9):365–378. doi:10.3109/01902148.2013.829537
   PubMed Web of Science ®Google Scholar
• Li ZG, Xie WB, Escano CS, et al. Response gene to complement 32 is essential for fibroblast activation in renal fibrosis. J Biol Chem. 2011;286(48):41323–41330. doi:10.1074/jbc.M111.259184
   PubMed Web of Science ®Google Scholar
• Luzina IG, Rus V, Lockatell V, et al. Regulator of cell cycle protein (RGCC/RGC-32) protects against pulmonary fibrosis. Am J Respir Cell Mol Biol. 2022;66(2):146–157. doi:10.1165/rcmb.2021-0022OC
   PubMed Web of Science ®Google Scholar
• Stapor PC, Azimi MS, Ahsan T, Murfee WL. An angiogenesis model for investigating multicellular interactions across intact microvascular networks. Am J Physiol Heart Circ Physiol. 2013;304(2):H235–45. doi:10.1152/ajpheart.00552.2012
   PubMed Web of Science ®Google Scholar
• Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol. 1999;144(4):789–801. doi:10.1083/jcb.144.4.789
   PubMed Web of Science ®Google Scholar
• Jackson DG. Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis. APMIS. 2004;112(7–8):526–538. doi:10.1111/j.1600-0463.2004.apm11207-0811.x
   PubMed Web of Science ®Google Scholar
• Akishima Y, Ito K, Zhang L, et al. Immunohistochemical detection of human small lymphatic vessels under normal and pathological conditions using the LYVE-1 antibody. Virchows Arch. 2004;444(2):153–157. doi:10.1007/s00428-003-0950-8
   PubMed Web of Science ®Google Scholar
• Alexander JS, Chaitanya GV, Grisham MB, Boktor M. Emerging roles of lymphatics in inflammatory bowel disease. Ann N Y Acad Sci. 2010;1207(Suppl 1):E75–E85. doi:10.1111/j.1749-6632.2010.05757.x.
   PubMedGoogle Scholar
• Alitalo K. The lymphatic vasculature in disease. Nat Med. 2011;17(11):1371–1380. doi:10.1038/nm.2545
   PubMed Web of Science ®Google Scholar
• Cui Y, Liu K, Lamattina AM, Visner G, El-Chemaly S. Lymphatic vessels: the next frontier in lung transplant. Ann Am Thorac Soc. 2017;14(Supplement_3):S226–S232. doi:10.1513/AnnalsATS.201606-465MG
   PubMedGoogle Scholar
• Stump B, Cui Y, Kidambi P, Lamattina AM, El-Chemaly S. Lymphatic changes in respiratory diseases: more than just remodeling of the lung? Am. J Respir Cell Mol Biol. 2017;57(3):272–279. doi:10.1165/rcmb.2016-0290TR
   PubMed Web of Science ®Google Scholar
• Wang L, Chen Q, Liu TT, et al. Role and mechanism of benzo[a]pyrene in the transformation of chronic obstructive pulmonary disease into lung adenocarcinoma. J Cancer Res Clin Oncol. 2023;149(8):4741–4760. doi:10.1007/s00432-022-04353-y
   PubMed Web of Science ®Google Scholar
• Nunomiya K, Shibata Y, Abe S, et al. Relationship between serum level of lymphatic vessel endothelial hyaluronan receptor-1 and prognosis in patients with lung cancer. J Cancer. 2014;5(3):242–247. doi:10.7150/jca.8486
   PubMed Web of Science ®Google Scholar
• Johnson LA, Prevo R, Clasper S, Jackson DG. Inflammation-induced uptake and degradation of the lymphatic endothelial hyaluronan receptor LYVE-1. JBio Chem. 2007;282(46):33671–33680. doi:10.1074/jbc.M702889200
   PubMed Web of Science ®Google Scholar
• Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005;6(5):322–327. doi:10.1016/S1470-2045(05)70168-6
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Gon Y, Takeshita I, Matsumoto K, Maruoka S, Horie T. Transforming growth Factor-beta1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-Jun-NH2-terminal kinase-dependent pathway. Am J Respir Crit Care Med. 2001;163(1):152–157. doi:10.1164/ajrccm.163.1.2005069
   PubMed Web of Science ®Google Scholar
• Guo H, Jian Z, Liu H, et al. TGF-β1-induced EMT activation via both Smad-dependent and MAPK signaling pathways in Cu-induced pulmonary fibrosis. Toxicol Appl Pharmacol. 2021;1(418):115500. doi:10.1016/j.taap.2021.115500
   Google Scholar
• Boucherat O, Landry-Truchon K, Aoidi R, et al. Lung development requires an active ERK/MAPK pathway in the lung mesenchyme. Dev Dyn. 2017;246(1):72–82. doi:10.1002/dvdy.24464
   PubMed Web of Science ®Google Scholar
• Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001;22(2):153–183. doi:10.1210/edrv.22.2.0428
   PubMed Web of Science ®Google Scholar
• Sun Y, Liu WZ, Liu T, Feng X, Yang N, Zhou HF. Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduction Res. 2015;35(6):600–604. doi:10.3109/10799893.2015.1030412
   PubMed Web of Science ®Google Scholar
• Kranz A, Kinner A, Kolling R, Pelham HRB. A family of small coiled-coil-forming proteins functioning at the late endosome in yeast. Mol Biol Cell. 2001;12(3):711–723. doi:10.1091/mbc.12.3.711
   PubMed Web of Science ®Google Scholar
• Shim JH, Xiao C, Hayden MS, et al. CHMP5 is essential for late endosome function and down-regulation of receptor signaling during mouse embryogenesis. J Cell Biol. 2006;172(7):1045–1056. doi:10.1083/jcb.200509041
   PubMed Web of Science ®Google Scholar
• Shahmoradgoli M, Mannherz O, Engel F, et al. Antiapoptotic function of charged multivesicular body protein 5: a potentially relevant gene in acute myeloid leukemia. Int, J, Cancer. 2011;128(12):2865–2871. doi:10.1002/ijc.25632
   PubMed Web of Science ®Google Scholar
• Nakova VV, Nakov Z, Dokuzova S, Prosheva T, Krstevska B. Efficacy and safety of empagliflozin and semaglutide (Once Weekly) in T2DM patients in shtip. Pril. 2023;44(1):71–77. doi:10.2478/prilozi-2023-0008
   PubMedGoogle Scholar
• Sivalingam S, Wasehuus VS, Curovic VR, et al. Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: a randomized and placebo-controlled study. Diabetes Obes Metab. 2024;26(1):54–64. doi:10.1111/dom.15287
   PubMed Web of Science ®Google Scholar
• Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 Diabetes, 2022. A consensus report by the American diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786. doi:10.2337/dci22-0034
   PubMed Web of Science ®Google Scholar
• Vernstrøm L, Gullaksen S, Sørensen SS, Funck KL, Laugesen E, Poulsen PL. Separate and combined effects of empagliflozin and semaglutide on vascular function: a 32-week randomized trial. Diabetes Obes Metab. 2024;19:doi:10.1111/dom.15464
   Google Scholar